A large national study led in part by researchers at Fox Chase Cancer Center has found that stomach cancer patients who respond especially well to chemotherapy given before surgery live significantly longer than those who do not.
A new international research collaboration led by investigators at Fox Chase Cancer Center and The University of Alabama is working to improve outcomes for patients with metastatic colorectal cancer by expanding representation in cancer research and identifying biological markers that may influence survival.
Sid Balachandran, PhD arrived in America with $97 and two suitcases. Decades later, his curiosity about how flu viruses kill cells led to an unexpected discovery that could help the immune system finally recognize and destroy cancer.
Fox Chase Cancer Center researchers found that adding an FDA-approved thyroid hormone after chemotherapy helped prevent tumor regrowth in laboratory and animal studies. This approach is now being tested in a national pediatric clinical trial for medulloblastoma.
A new Fox Chase Cancer Center study examining nursing resignations during and after the COVID-19 pandemic found that many early-career nurses left or considered leaving the profession due to inadequate institutional support, diminished clinical readiness, emotional strain, and misalignment between expectations and real-world practice.
A new study from researchers at Fox Chase Cancer Center and collaborators across multiple institutions has identified a hidden subset of lung cancers that behave more like aggressive neuroendocrine tumors than traditional non-small cell lung cancer (NSCLC).
In a new Fox Chase Cancer Center study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Anthony Olszanski, MD, RPh, and colleagues evaluated gamitrinib, an experimental therapy designed to exploit this vulnerability. Gamitrinib is a first-in-class therapy engineered to act inside cancer cell mitochondria, disrupting key survival functions tumors use to grow and resist treatment.